Nicholas Sluss, PA
Physician Assistant · Norton, VANPI 1093924201
Payments from drug & device makers
Across 396 payments — averaging $15.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$980
- AstraZeneca$492
- Pfizer$468
- Lilly USA, LLC$401
- Abbott$326
- plus $2K from 29 others
What the payments were for
- Food & beverage$6,059100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 86 | $1,112 |
| AbbVie | 73 | $980 |
| AstraZeneca | 28 | $492 |
| Pfizer | 34 | $468 |
| Lilly USA, LLC | 26 | $401 |
| Abbott | 19 | $326 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $264 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $252 |
| Bayer | 11 | $197 |
| GSK | 12 | $185 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $170 |
| Amgen | 8 | $135 |
| Novartis | 7 | $121 |
| Merck | 7 | $115 |
| Johnson & Johnson | 5 | $87 |
| Lundbeck LLC | 3 | $64 |
| Biohaven Pharmaceuticals, Inc. | 4 | $62 |
| Astellas Pharma US Inc | 3 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| Amarin Pharma, Inc. | 3 | $55 |
| Vanda Pharmaceuticals Inc. | 3 | $51 |
| Phathom Pharmaceuticals, Inc. | 2 | $51 |
| Corium, LLC | 2 | $46 |
| Otsuka America Pharmaceutical, Inc. | 3 | $44 |
| Gilead | 1 | $43 |
| Dexcom, Inc. | 1 | $35 |
| Nestle Healthcare Nutrition Inc. | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Boehringer Ingelheim | 1 | $26 |
| Sumitomo Pharma America, Inc. | 2 | $22 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Ardelyx, Inc. | 1 | $17 |
| Antares Pharma, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Scilex Pharmaceuticals Inc. | 1 | $14 |
How this compares
$6,059 in reported general payments places this provider in the 90th percentile of 3,376 physician assistant providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 39 | $37,949 |
| JanuviaSitagliptin Phosphate | 33 | $34,406 |
| EliquisApixaban | 46 | $33,938 |
| RybelsusSemaglutide | 23 | $27,155 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $16,745 |
| FarxigaDapagliflozin Propanediol | 13 | $13,166 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $12,700 |
| TrulicityDulaglutide | 11 | $11,713 |
| MounjaroTirzepatide | 11 | $11,617 |
| VascepaIcosapent Ethyl | 24 | $11,323 |
| LinzessLinaclotide | 15 | $8,837 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 320 | $7,010 |
| JardianceEmpagliflozin | 12 | $6,800 |
| XareltoRivaroxaban | 12 | $6,403 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 140 | $4,260 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,112 | $65,10362 claims |
| MerckJanuvia | $115 | $34,40633 claims |
| PfizerEliquis | $468 | $33,93846 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $401 | $23,33022 claims |
| GSKTrelegy Ellipta | $185 | $16,74526 claims |
| AstraZenecaFarxiga | $492 | $13,16613 claims |
| AbbVieLinzess | $980 | $8,83715 claims |
| Boehringer IngelheimJardiance | $26 | $6,80012 claims |
| Johnson & JohnsonXarelto | $87 | $6,40312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,376 physician assistant providers in Virginia.
Other physician assistant in Norton
- John DalessandroSalem$160K
- Jalal AlghabraFredericksburg$119K
- Jamie GiovanelliVirginia Beach$118K
- John CarterStaunton$90K
- Melissa AlcoxNorfolk$73K
- Lindsay TomReston$71K
- Robert HigginsonRichmond$66K
- Jameka McElroy-BrooklynArlington$65K
- Hillary HartungNorfolk$62K
- Juliette BeristainVirginia Beach$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.